Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00008073 · ClinicalTrials.gov registry record · Phase 1
Octreotide and Doxorubicin in Treating Patients With Advanced Cancer
A Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00008073: Completed Phase 1 study, sponsored by University of Pittsburgh.
NCT00008073 is a Phase 1 study that has completed, run by University of Pittsburgh. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00008073, a Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Octreotide may help doxorubicin kill more cancer cells by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of octreotide and doxorubicin in treating patients who have advanced cancer.
Interventions
- DRUG doxorubicin hydrochloride
- DRUG octreotide acetate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-01 |
| Est. Completion | 2002-05 |
| Phase | Phase 1 |
What the finished NCT00008073 record still lists
NCT00008073 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which doxorubicin hydrochloride is the first listed.
NCT00008073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00008073 about?
NCT00008073 is a clinical study titled "Octreotide and Doxorubicin in Treating Patients With Advanced Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Octreotide may help doxorubicin kill more cancer cells by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of octreotide and doxoru...
What is the current status of trial NCT00008073?
This trial is currently completed. It is a Phase 1 study. The study started on 1996-01. Estimated completion is 2002-05.
What interventions are being tested in trial NCT00008073?
The interventions under investigation include: doxorubicin hydrochloride (DRUG), octreotide acetate (DRUG).
Who is sponsoring clinical trial NCT00008073?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia